EUVIMEDEUVIMED entdecken
Systematische Übersicht

Rethinking glycemic monitoring: a HTA of glycated albumin for type 2 diabetes with stage IV–V CKD

Lucrezia Ferrario, Emanuela Foglia

Endocrine · 30.10.2026 · 91 (1)

DOI: 10.1007/s12020-026-04844-9 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Endocrine, online erschienen am 30.10.2026. Verfasst von Lucrezia Ferrario und 1 weiteren Autor:innen. Beteiligte Einrichtung: Healthcare Datascience LAB, LIUC - Università Cattaneo, Castellanza, Italy. lferrario@liuc.it. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Serum Albumin. Die Arbeit nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aims to evaluate the multidimensional implications of introducing glycated albumin (GA) into Italian clinical practice as an innovative glycemic marker for monitoring type 2 diabetes mellitus (T2DM) in patients with stage IV–V chronic kidney disease (CKD), compared with the current gold standard, glycated haemoglobin (HbA1c).

Methods

A Health Technology Assessment (HTA) was conducted from the perspective of the Italian National Health Service (NHS), adopting the EUnetHTA Core Model framework and using a comparative approach to assess the clinical and non-clinical domains of clinical pathways with and without the inclusion of GA. The analysis integrated evidence from a systematic literature review, health economics evaluations, and stakeholder perceptions gathered through validated questionnaires.

Results

The systematic literature review demonstrated that GA more accurately identifies poor glycaemic control than HbA1c alone (52% vs. 19.2%), with benefits in reducing adverse events, in T2DM patients with advanced CKD. From an economic point of view, GA would lead to an overall economic saving equal to 2.02%, on annual basis, thus representing the strategy with the most favorable trade-off between costs and effectiveness. Healthcare professionals’ perceptions (collected using a 7-point Likert scale, ranging from −3 to + 3), confirmed these findings, with higher ratings for GA in terms of safety (1.60 vs. 1.01) and effectiveness (2.12 vs. 1.02). Improvements were also reported in perceived quality of life for both patients and caregivers (2.00 vs. 0.88). Organizationally, although minimal investments would be required for training and equipment updates, the adoption of GA was associated with a significant enhancement in the management of the patient care pathway (2.25 vs. 0.63).

Conclusions

The results highlight the strategic value of GA as a complementary biomarker in the monitoring of glycemic control among T2DM patients with advanced CKD, offering clinical benefits and potential efficiency gains for the healthcare system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Renal Insufficiency, ChronicSerum AlbuminHumansGlycated Serum AlbuminGlycation End Products, AdvancedGlycated HemoglobinTechnology Assessment, BiomedicalBlood GlucoseGlycemic ControlItalyContinuous Glucose Monitoring

Stichwörter der Autor:innen

Chronic kidney diseaseDiabetesEconomic sustainabilityGlycemic controlHealth technology assessmentItaly

Substanzen

Glycated Serum AlbuminSerum AlbuminGlycation End Products, AdvancedGlycated HemoglobinBlood Glucose

Autor:innen und Institutionen

  • Healthcare Datascience LAB, LIUC - Università Cattaneo, Castellanza, Italy. lferrario@liuc.it.
  • Healthcare Datascience LAB, LIUC - Università Cattaneo, Castellanza, Italy.

Zitieren

APA

Ferrario, L., & Foglia, E. (2026). Rethinking glycemic monitoring: a HTA of glycated albumin for type 2 diabetes with stage IV–V CKD. Endocrine, 91(1). https://doi.org/10.1007/s12020-026-04844-9

Vancouver

Ferrario L, Foglia E. Rethinking glycemic monitoring: a HTA of glycated albumin for type 2 diabetes with stage IV–V CKD. Endocrine. 2026;91(1). doi:10.1007/s12020-026-04844-9

BibTeX
@article{Ferrario2026,
  author = {Ferrario, Lucrezia and Foglia, Emanuela},
  title = {Rethinking glycemic monitoring: a HTA of glycated albumin for type 2 diabetes with stage IV–V CKD},
  journal = {Endocrine},
  year = {2026},
  volume = {91},
  number = {1},
  doi = {10.1007/s12020-026-04844-9}
}
Kostenlos starten →